Future Research Priorities for Morbidity Control of Lymphedema

BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered...

Descripción completa

Detalles Bibliográficos
Autores principales: Narahari, S R, Aggithaya, Madhur Guruprasad, Moffatt, Christine, Ryan, T J, Keeley, Vaughan, Vijaya, B, Rajendran, P, Karalam, S B, Rajagopala, S, Kumar, N K, Bose, K S, Sushma, K V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286751/
https://www.ncbi.nlm.nih.gov/pubmed/28216723
http://dx.doi.org/10.4103/0019-5154.198039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286751/
https://www.ncbi.nlm.nih.gov/pubmed/28216723
http://dx.doi.org/10.4103/0019-5154.198039

Ejemplares similares